ArticleAnnals of clinical and translational neurology2018
Alzheimer's genetic risk is reduced in primary age-related tauopathy: a potential model of resistance?
Article in Annals of clinical and translational neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Primary age-related tauopathy.Acta neuropathologica · 2025Review
- Sequence and trajectory of early Alzheimer's disease-related tau inclusions in the hippocampal formation of cases without amyloid-β deposits.Acta neuropathologica · 2025Article
- Lewy body co-pathology in Alzheimer's disease and primary age-related tauopathy contributes to differential neuropathological, cognitive, and brain atrophy patterns.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Review
- Histopathologic brain age estimation via multiple instance learning.Acta neuropathologica · 2023Article
- Cognitive and Neuropsychological Profiles in Alzheimer's Disease and Primary Age-Related Tauopathy and the Influence of Comorbid Neuropathologies.Journal of Alzheimer's disease : JAD · 2023Article
- Hypothesis review: Alzheimer's overture guidelines.Brain pathology (Zurich, Switzerland) · 2023Review
- Alzheimer's disease is an inherent, natural part of human brain aging: an integrated perspective.Free neuropathology · 2022Article
- Genome-wide association study and functional validation implicates JADE1 in tauopathy.Acta neuropathologica · 2022Article
- Dysregulated protein phosphorylation: A determining condition in the continuum of brain aging and Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2021Article
- The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's disease assessed with positron emission tomography.Science translational medicine · 2021Article
- Associations of Alzheimer's disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration.Alzheimer's research & therapy · 2021Article
- Chronic Traumatic Encephalopathy and Neuropathological Comorbidities.Seminars in neurology · 2020Review
- Amyloid-β-independent regulators of tau pathology in Alzheimer disease.Nature reviews. Neuroscience · 2020Review
- Neuropathology of the Alzheimer's continuum: an update.Free neuropathology · 2020Article
- The characterization of AD/PART co-pathology in CJD suggests independent pathogenic mechanisms and no cross-seeding between misfolded Aβ and prion proteins.Acta neuropathologica communications · 2019Article
- UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis.Neurobiology of aging · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveNearly all adults >50 years of age have evidence for neurofibrillary tau tangles (NFTs) and a significant proportion of individuals additionally develop amyloid plaques (A
methodsGeneral linear models assessed the odds of AD (
resultsThree genotypes significantly associated with reduced AD risk relative to PART in the PENN (
interpretationThe presence of genotypic differences between PART and AD suggest that PART can provide a genetic model of NFT risk and potential A
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.